195 related articles for article (PubMed ID: 15238146)
1. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Br J Haematol; 2004 Jul; 126(2):244-51. PubMed ID: 15238146
[TBL] [Abstract][Full Text] [Related]
2. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
3. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
Wada N; Maeda H; Yoshimine Y; Akamine A
Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
[TBL] [Abstract][Full Text] [Related]
4. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones.
Ikeda T; Utsuyama M; Hirokawa K
J Bone Miner Res; 2001 Aug; 16(8):1416-25. PubMed ID: 11499864
[TBL] [Abstract][Full Text] [Related]
6. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint.
Carda C; Silvestrini G; Gomez de Ferraris ME; Peydró A; Bonucci E
Tissue Cell; 2005 Jun; 37(3):247-55. PubMed ID: 15899507
[TBL] [Abstract][Full Text] [Related]
8. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
Tian QX; Huang GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268
[TBL] [Abstract][Full Text] [Related]
9. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey EL; Williams JH; Davie MW; Marshall MJ
Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558
[TBL] [Abstract][Full Text] [Related]
10. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
11. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S
Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519
[TBL] [Abstract][Full Text] [Related]
12. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis.
Fazzalari NL; Kuliwaba JS; Atkins GJ; Forwood MR; Findlay DM
J Bone Miner Res; 2001 Jun; 16(6):1015-27. PubMed ID: 11393778
[TBL] [Abstract][Full Text] [Related]
13. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.
Tsangari H; Findlay DM; Kuliwaba JS; Atkins GJ; Fazzalari NL
Bone; 2004 Jul; 35(1):334-42. PubMed ID: 15207775
[TBL] [Abstract][Full Text] [Related]
15. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA.
Baumann B; Rader CP; Seufert J; Nöth U; Rolf O; Eulert J; Jakob F
Acta Orthop Scand; 2004 Jun; 75(3):295-302. PubMed ID: 15260421
[TBL] [Abstract][Full Text] [Related]
16. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland.
Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE
J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731
[TBL] [Abstract][Full Text] [Related]
17. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis.
Pettit AR; Walsh NC; Manning C; Goldring SR; Gravallese EM
Rheumatology (Oxford); 2006 Sep; 45(9):1068-76. PubMed ID: 16490750
[TBL] [Abstract][Full Text] [Related]
18. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin.
Bock O; Loch G; Schade U; Büsche G; Wasielewski R; Wiese B; Kreipe H
Br J Haematol; 2005 Jul; 130(1):76-82. PubMed ID: 15982347
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.
Cheung J; Mak YT; Papaioannou S; Evans BA; Fogelman I; Hampson G
J Endocrinol; 2003 Jun; 177(3):423-33. PubMed ID: 12773123
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
